October 02, 2024
4 min watch
Save
VIDEO: Ocular Therapeutix provides update on Axpaxli studies
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio Video Perspective from the Retina Society meeting, Pravin U. Dugel, MD, of Ocular Therapeutix shares positive updates on studies investigating Axpaxli, an axitinib implant for the treatment of retinal diseases.
Dugel discussed the phase 3 SOL-1 and SOL-R studies for wet age-related macular degeneration and the phase 1 HELIOS study for diabetic retinopathy.
According to written FDA feedback, “SOL-1 and SOL-R are sufficient to approve Axpaxli, so no further studies are required,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Dugel reports being the CEO of Ocular Therapeutix.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.